Keytruda Market By Indication (Melanoma, Non-small cell lung cancer (NSCLC), Head and neck cancer, Hodgkin lymphoma, Bladder cancer, Others), By Treatment Type (Monotherapy, Combination therapy), By Route of Administration (Intravenous (IV) Injection, Subcutaneous Injection), By Strength (50 mg per vial, 100 mg per vial), By Distribution Channel (Direct Sales, Distributors and Wholesalers, Retail Pharmacies, Hospital Pharmacies), and By End-user (Hospitals, Oncology clinics, Research institutions, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Indication

• Melanoma
• Non-small cell lung cancer (NSCLC)
• Head and neck cancer
• Hodgkin lymphoma
• Bladder cancer
• Others

By Treatment Type

• Monotherapy
• Combination therapy

By Route of Administration

• Intravenous (IV) Injection
• Subcutaneous Injection

By Strength

• 50 mg per vial
• 100 mg per vial

By Distribution Channel

• Direct Sales
• Distributors and Wholesalers
• Retail Pharmacies
• Hospital Pharmacies

By End User

• Hospitals
• Oncology clinics
• Research institutions
• Others

By Region

North America

• The U.S.
• Canada

Europe

• Germany
• France
• U.K.
• Italy
• Spain

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea

Latin America

• Brazil
• Argentina
• Mexico

MEA

• Saudi Arabia
• United Arab Emirates
• South Africa

List of Companies

• Merck & Co., Inc.
• Bristol Myers Squibb
• Roche
• AstraZeneca
• Pfizer
• Novartis
• Eli Lilly and Company
• Johnson & Johnson
• Regeneron Pharmaceuticals
• Amgen